0
0
ABBOTT PARK, Ill. – May 27, 2025 – Abbott Laboratories (NYSE: ABT) today announced that its Tendyne™ Transcatheter Mitral Valve Replacement (TMVR) system has received U.S. Food and Drug Administration (FDA) approval. This groundbreaking development offers a new, minimally invasive treatment option for patients suffering from severe mitral valve disease, particularly those with severe mitral annular calcification (MAC) who are considered high-risk for traditional open-heart surgery.
The Tendyne system is designed to replace a leaky (mitral regurgitation) or narrowed (stenosis) mitral valve without the need for open-heart surgery. This is a significant advancement for individuals whose mitral valves are not functioning properly due to a buildup of calcium within the valve’s supporting ring-like structure, known as the annulus. Such complex conditions often pose considerable challenges for surgical correction.
For patients with severe MAC who face high risks associated with open-heart surgery, and for whom Abbott’s existing MitraClip™ device is not a viable solution, the Tendyne system provides a crucial alternative. The device is a self-expanding, tri-leaflet bioprosthetic valve that can be precisely placed during implantation and is fully repositionable and retrievable, allowing for optimal placement and potentially improved patient outcomes.
Abbott has been at the forefront of developing transcatheter mitral valve technologies. The Tendyne system builds upon the company’s extensive experience with its MitraClip device, which is a leading approved therapy for mitral valve repair. The approval of Tendyne™ broadens Abbott’s portfolio, providing physicians with a choice of treatment options – repair or replacement – depending on the patient’s specific needs and valve anatomy.
Clinical trials, including the global SUMMIT study, have evaluated the safety and efficacy of the Tendyne TMVR system. Earlier results from a separate global study of the Tendyne device demonstrated promising outcomes, with a significant reduction in symptoms of mitral regurgitation and low mortality rates observed at 30 days.
This FDA approval marks a pivotal moment for patients with severe mitral valve disease who previously had limited treatment options. It underscores Abbott’s commitment to developing innovative, life-changing therapies that improve health outcomes and quality of life.
Disclaimer: This article is based on publicly available information and news releases. While the information presented is believed to be accurate as of the date of publication, medical advancements and regulatory statuses can change. Patients should always consult with their healthcare providers to discuss their individual medical conditions and the most appropriate treatment options. The content herein is for informational purposes only and does not constitute medical advice.
